Analysts See $-0.11 EPS for Presbia PLC (LENS)

July 14, 2018 - By Jack Shaw

Investors sentiment increased to Infinity in Q1 2018. Its up Infinity, from 0.67 in 2017Q4. It improved, as 0 investors sold Presbia PLC shares while 0 reduced holdings. 2 funds opened positions while 3 raised stakes. 5.31 million shares or 100.41% more from 2.65 million shares in 2017Q4 were reported.
New York-based Blackrock has invested 0% in Presbia PLC (NASDAQ:LENS). 14,898 were accumulated by Geode Limited Com. 686 were accumulated by Commercial Bank Of America De. Barclays Public Ltd Co reported 59 shares. Royal Financial Bank Of Canada owns 2 shares for 0% of their portfolio. Amundi Pioneer Asset Incorporated owns 11,900 shares for 0% of their portfolio. Morgan Stanley reported 2,382 shares or 0% of all its holdings. Fmr Ltd Company owns 2.57M shares. Vanguard Gru invested in 0% or 54,457 shares.

Analysts expect Presbia PLC (NASDAQ:LENS) to report $-0.11 EPS on August, 10.They anticipate $0.16 EPS change or 59.26 % from last quarter’s $-0.27 EPS. After having $-0.12 EPS previously, Presbia PLC’s analysts see -8.33 % EPS growth. The stock increased 3.12% or $0.0645 during the last trading session, reaching $2.1345. About 8,361 shares traded. Presbia PLC (NASDAQ:LENS) has declined 13.21% since July 14, 2017 and is downtrending. It has underperformed by 25.78% the S&P500.

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company has market cap of $36.55 million. The firm provides the refractive lens for patient surgeries, as well as accessories for procedures. It currently has negative earnings. It primarily operates in South Korea, Australia, the Netherlands, Ireland, and Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.